Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Capital Expenditures (2016 - 2025)

Immucell's Capital Expenditures history spans 16 years, with the latest figure at -$1.1 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 304.94% year-over-year to -$1.1 million; the TTM value through Dec 2025 reached $4685.0, up 5.97%, while the annual FY2025 figure was $4685.0, 5.97% up from the prior year.
  • Capital Expenditures reached -$1.1 million in Q4 2025 per ICCC's latest filing, down from $593924.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.8 million in Q4 2023 to a low of -$1.3 million in Q3 2023.
  • Average Capital Expenditures over 5 years is $424277.1, with a median of $634662.0 recorded in 2021.
  • The largest YoY upside for Capital Expenditures was 571.77% in 2025 against a maximum downside of 304.94% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $704594.0 in 2021, then soared by 111.49% to $1.5 million in 2022, then grew by 19.27% to $1.8 million in 2023, then crashed by 114.91% to -$265088.0 in 2024, then tumbled by 304.94% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Capital Expenditures are -$1.1 million (Q4 2025), $593924.0 (Q3 2025), and $155159.0 (Q2 2025).